Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

Overview
Date Founded

2003

Headquarters

270 EAST GRAND AVENUE, SUITE 22, SOUTH SAN FRANCISCO, CA, 94080

Type of Company

Public

Employees (Worldwide)

324

Industries

Pharmaceuticals
Pension Funds & Sovereign Wealth
Medical Products & Equipment
Biotechnology

Company Description

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Contact Data
Trying to get in touch with decision makers at Portola Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President, Chief Financial Officer & Chief Business Officer

Executive Vice President, General Counsel & Secretary

Executive Vice President, Chief Commercial Officer

Executive Vice President & Chief Human Resources Officer

Interim Chief Medical Officer

Executive Vice President, Chief Technical Operations Officer

Senior Vice President, Medicinal Chemistry & Chemical Development

Senior Vice President of Research

Vice President, Program Management

Board of Directors

Former President & Chief Executive Officer at Onyx Pharmaceuticals, Inc.

President & Chief Executive Officer at Global Blood Therapeutics, Inc.

Member, Board of Directors & Audit Committee at Pacira Pharmaceuticals, Inc. - California

Consultant at Sunesis Pharmaceuticals, Inc.

Chief Executive Officer at Fenton & Associates LLC

Former Senior Vice President at Eli Lilly & Company

Managing Director at Sutter Hill Ventures LLC

Former Executive Vice President, Chief Financial Officer & Chief Accounting Officer at Sangamo Therapeutics, Inc.

President & Chief Executive Officer at Portola Pharmaceuticals, Inc.

Executive Director, Corporate Counsel & Assistant Corporate Secretary at Portola Pharmaceuticals, Inc.

Paths to Portola Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Portola Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Cadian Capital Management manages funds which seek long-term capital appreciation from investments in equity securities of companies in the global telecommunications, media and technology sectors as well as in consumer, healthcare, industrials, financial services and technology and other related sectors. To implement the funds' strategy, Cadian focuses on fundamental stock research and selection through a disciplined upside/downside analysis. They take a value-oriented approach to the sectors in which the funds invest, drawing upon the deep sector expertise of its personnel across geographies and asset classes. The firm focuses on minimizing market and other systemic risks to the funds' portfolios. Cadian seeks conservative net beta exposure through alpha generative long and short positions.Although the funds may hold non-diversified and relatively concentrated portfolios, the primary focus of the funds is to invest in common stocks. Opportunities to enhance capital appreciation are pursued through the use of both long and short positions, margin borrowing, derivatives and other instruments or securities. Depending on market conditions and available investment opportunities, the funds' portfolios may be concentrated in some or all of the sectors listed above or, alternatively, the funds may focus on investment opportunities in other unrelated sectors. Cadian may also make use of various hedging techniques that might include, but are not limited to, currency hedging, short sales, and the writing of stock options and options on stock market indices (and/or investing directly in these indices).

Details Hidden

Part of Tamarack Capital GP LLC, Tamarack Advisers LP is a company headquartered in Carlsbad, CA. The firm provides investment advice. Justin John Ferayorni has been the CEO since 2015.

Details Hidden

About Us Highland Capital Management, L.P. is an SEC-registered investment adviser which, together with our affiliates, has approximately $20 billion of assets under management. We are one of the largest and most experienced global alternative credit managers. Our firm specializes in credit strategies, such as credit hedge funds, long-only funds and separate accounts, distressed control private equity, and collateralized loan obligations (CLOs). Highland also offers alternative investments, including emerging markets, long/short equities, and natural resources. Highland's diversified client base includes public pension plans, foundations and endowments, corporations, financial institutions, fund of funds, governments, and high net-worth individuals. Our firm is headquartered in Dallas, Texas and maintains offices in New York, London, Singapore, and Seoul

Recent Transactions
Details Hidden

Portola Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Portola Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Portola Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onPortola Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onPortola Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onPortola Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onPortola Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onPortola Pharmaceuticals, Inc. issued USD Common Stock

Investment Banking Analyst

Advised onPortola Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, Palo Alto at Cooley LLP

Consultant

Former Executive Vice President, Head-Research & Development at Portola Pharmaceuticals, Inc.

Legal Advisor

Partner at Davis Polk & Wardwell LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Key Stats and Financials As of 2018
Market Capitalization
$1.89B
Total Enterprise Value
$1.2B
Earnings Per Share
$-5.31
Revenue
$40.1M
Net Profit
$-350M
EBITDA
$-342M
EBITDAMargin
-852.77%
Total Debt
$223M
Total Equity
$90.6M
Enterprise Value Sales
29.8x
TEVNet Income
-3.41x
Debt TEV
0.19x
Three Year Compounded Annual Growth Rate Of Revenue
49.25%
Five Year Compounded Annual Growth Rate Of Revenue
30.68%
Investors
Details Hidden

Prospect Venture Partners focuses on investments in commercially attractive biomedical technology and life science companies that have management teams, proprietary products and innovative technology or services. They participate in new company incubations,seed, first and second venture financing rounds and expansion capital financings of later-stage private and public companies with proven business models. Initial investments range from $500,000 to $10 million with $10 million to $20 million invested over the life of a company. Prospect Venture Partners will serve as a lead investor or as a co-lead in a syndicate. The firm typically takes a seat on the boards of their portfolio companies.

Details Hidden

MPM invests in companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. The firm portfolio companies aims to revolutionize the face of medicine across multiple areas including cancer, diabetes, obesity, pain, eHealth and more. With their experienced and dedicated team of operating executives and medical and scientific advisory board they are powering novel medical breakthroughs that transform patient lives.

Details Hidden

AB's investment analysts create proprietary research to support our portfolio managers, who also can conduct their own research. Their portfolio management professionals then implement our discretionary investment strategies. The firm's professionals employ a range of investment strategies to implement the advice they give to clients including: long-term purchases, short-term purchases, trading, short sales, margin transactions, option strategies including writing covered options, uncovered options and spread strategies, and taking advantage of price differentials between two or more securities (arbitrage). Quantitative analytics are utilized in some of AB's investment activities, to assist in the selection of securities or the management of investment risk. It is often necessary for them to acquire or dispose of the same securities for more than one client account at the same time. In conducting security analysis, they utilize a broad spectrum of information, including without limitation financial publications, third-party research materials, annual reports, prospectuses, regulatory filings, company press releases, corporate rating services, inspections of corporate activities and meetings with management of various companies.

Suppliers
Lonza Group AG Pharmaceuticals | Basel, BS

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Hovione Farmaciência SA Wholesale: Consumer Non-Durables/Sundries | Loures, LI

Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal.

Astellas Pharma, Inc. Hospitals & Patient Services | Tokyo, TY

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company is headquartered in Tokyo, Japan.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Seattle Genetics, Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Portola Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Portola Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Portola Pharmaceuticals, Inc..